Skip navigation
Skip navigation
You are using an outdated browser. Please upgrade your browser.
ReCell® Spray-On Skin®

Cambridge, United Kingdom, 13 February 2012—Avita Medical Ltd. (ASX: AVH): A ground-breaking technique which turns a tiny sample of a patient’s skin into a spray-on treatment for large-scale skin regeneration is revolutionising the way surgeons are able to treat burns, hard-to-heal wounds and skin trauma as well as giving new hope to patients with scars.

ReCell® Spray-On Skin®, which has been developed by Cambridge-based Avita Medical (ASX: AVH), is a unique, patented process which transforms a thin, split-thickness biopsy from the patient’s own skin into a cell suspension that can be immediately sprayed or dripped onto wounds to stimulate healthy new skin growth.

Using the ReCell® incubation and processing device, within 20 minutes a 2cm square skin sample can create a cell suspension able to treat an area 80 times ¹.² the size of the biopsy (about the size of an A4 sheet of paper). The solution looks like water but contains millions of microscopic skin cells which, when sprayed on to a wound, will multiply and grow into a natural layer of new skin that will be similar in tone and texture ³.⁴ to surrounding skin. In addition, unlike scar tissue, the new skin will stretch and grow completely normally.

The first use of ReCell® has been in burns units to help speed up wound closure as it enables a natural layer of normal skin to develop, typically in a matter of 5-7 days ⁵,⁶,⁷. This helps to minimise scaring, reduce the risk of infection and enables patients to have a shorter hospital stay ¹ and get back to normal life more quickly. For burns patients who often need to spend long periods in hospital – up to a month in serious cases – this makes a huge difference to their short and long term recovery while providing significant savings to the healthcare system.

Not only does ReCell® deliver rapid skin growth ⁵,⁶,⁷, it also has the ability to form skin that matches the texture and colour ³,⁴ of the surrounding area so its potential to help in plastics, reconstructive, cosmetic and even vascular surgery is now being fully explored.

Jeremy Rawlins, consultant plastic surgeon at Mid Yorkshire Hospitals NHS Trust said: “This technology came out of needing to use cell-based therapies to treat patients with major burn injuries that were life threatening. That’s still a main stay but there are lots of different areas in which we are now using it, both acutely in terms of injuries but also in reconstructive and aesthetic patients as well; for instance, with patients who come to us with problematic scars many years after a burn injury.”

With these new wider applications, ReCell® is not only revolutionising treatment but also helping to tackle the potentially devastating psychological and quality of life issues that patients can face following an accident or surgery.

Consultant Zahida Butt has successfully used ReCell® at her clinic in Norwich to treat a range of skin problems. She said: “Burns, surgical scars, acne scaring: they all have very psychological impacts on patients. Although you are treating the skin primarily, you are also helping these patients to improve their quality of life. No other treatment works like this.”

To find out more about ReCell® visit a new, dedicated information site at


Avita Medical ( a leading global healthcare headquartered in Cambridge, UK, develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Using patented and proprietary tissue-culture, collection and application technology, the company is able to provide innovative treatment solutions derived from a patient’s own skin. The company’s lead product, ReCell Spray-On Skin, has been designed for use in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited by federal law to investigational use.

This news release may include forward-looking statements that involve risks and uncertainties. You can identify these statements by the use of words such as “anticipate”, “estimate”, “expect”, “project”, “potential”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. These forward-looking statements speak only as at the date of this release and are based on management’s expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of Avita Medical that could cause actual results to differ materially from such statements. Avita Medical makes no undertaking to subsequently update or revise the forward-looking statements made in this release to reflect events or circumstances after the date of this release. This document is intended to provide background information only and does not purport to make any recommendation upon which you may reasonably rely without taking further and more specific advice.



1. Gravante G, Di Fede MC, Araco A, Grimaldi M, De Angelis B, Arpino A, Cervelli V, Montone A. “A randomized trial comparing ReCell® system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns”. Burns. 2007 Dec; 33(8):966-72. Epub 2007 Sept 29
2. Wood FM. (2010), “Chapter 6” - H Hyakusoku et al (eds), “Colour Atlas of Burn Reconstructive Surgery”, Springer-Verlag Berlin Heidelberg 2010
3. Goodman G. “An automated autologous cell transplantation method for treatment of hypopigmented scarring”. Dermatology Surgery 2008; 34:579-581
4. Cervelli V, De Angelis B, Spallone D, Lucarini L, Arpino A, Balzani A. “Use of a novel autologous cell-harvesting device to promote epithelialization and enhance appropriate pigmentation in scar reconstruction”. Clinical and Experimental Dermatology 2010 Oct; 35(7):776-80
5. Navarro FA, Stoner ML, Park CS et al: “Sprayed keratinocyte suspensions accelerate epidermal coverage in a porcine microwound model”. J Burn Care & Rehabilitation. 2000 Nov-Dec; 21(6):513-8
6. Navarro FA, Stoner ML, Lee HB et al: “Melanocyte repopulation in full thickness wounds using a cell spray apparatus”. J Burn Care Rehabilitation. 2001 Jan-Feb; 22(1):41-6
7. Stoner ML, Wood FM: “The treatment of hypopigmented lesions with cultured epithelial autograft”. J Burn Care Rehabilitation. 2000 Jan-Feb; 21(1 Pt 1):50-4

For further information, clinical papers, interviews and case studies, please contact:- Alison Miles, Eurocom Healthcare Communications on 07900 691116 Email:

This press release was distributed by ResponseSource Press Release Wire on behalf of Eurocom Healthcare Communications in the following categories: Health, Women's Interest & Beauty, Medical & Pharmaceutical, for more information visit